Jazz Hits Teva With Patent Suit Over Narcolepsy Drug

By Carla Baranauckas · August 29, 2024, 3:40 PM EDT

Teva Pharmaceuticals Inc. is infringing a patent for the narcolepsy drug Xywav, Jazz Pharmaceuticals Inc. said in a complaint filed in New Jersey federal court....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

JAZZ PHARMACEUTICALS IRELAND LIMITED v. TEVA PHARMACEUTICALS, INC.

Case Number

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

August 27, 2024

Recent Articles By Carla

December 20, 2024
Top NJ Cases Of 2024: COVID Test Kits And Political Favors
December 06, 2024
Fox Rothschild Can't Escape Malpractice Suit Over Land Row
November 27, 2024
Nonprofit Warns 3rd Circ. Against 'Abuse' In Merck Vax Case
November 18, 2024
Nursing Home Owner Pleads Guilty A 2nd Time To Tax Fraud
November 07, 2024
Teva Fails To Convince Judge Inhaler Patents Require Drug
November 05, 2024
Bankruptcy Not Delaying NJ Health System's Antitrust Case
October 25, 2024
NJ Ethics Board Faces Contempt Bid In Retaliation Fight
October 18, 2024
Hospital, Medical Practice Ink $12M Deal In Brain Damage Suit
September 20, 2024
3rd Circ. Rejects 'Close' Case For Preemption In Fosamax MDL
August 14, 2024
Doctor Loses Challenge To Nursing Home's Vax Policy